Website Update: Email Subscriptions Discontinued

  Website Update: Email Subscriptions Discontinued I want to share an important update regarding email subscriptions and newsletters on Arácnido Taxonomy. Effective immediately, I have discontinued using Mailchimp for email newsletter subscriptions. Over the past several days, the subscription system and associated website functions have been subjected to persistent automated bot activity and attempted exploitation. In addition to generating unwanted subscription activity, these requests have contributed to periods of reduced website performance. To help protect the website, its content, and legitimate visitors, the Mailchimp subscription and registration functions have been removed. Following Arácnido Taxonomy via RSS For the foreseeable future, RSS will be the primary way to subscribe to and follow new posts and updates from Arácnido Taxonomy. RSS provides a simple, direct way to receive new content without submitting an email address or creating an account. Once the Arácnido Ta...

A comprehensive preclinical assessment of Viekvin antivenom: evaluation of neutralization efficacy and cross-reactivity toward European snake venoms

 


A comprehensive preclinical assessment of Viekvin antivenom: evaluation of neutralization efficacy and cross-reactivity toward European snake venoms

Abstract

In this study, the equine-derived F(ab′)2-based antivenom Viekvin, produced against V. ammodytes venom (Institute of Virology, Vaccines and Sera “Torlak”, Belgrade), was evaluated for its cross-reactivity and neutralization of enzymatic and toxic activities of venoms from Vipera ammodytesVipera berusVipera aspisMacrovipera lebetina, and Montivipera xanthina.
To characterize the antivenom’s activity, various in vitro assays were implemented, including enzymatic activity measurements of snake venom metalloproteinases (SVMPs), serine proteases (SVSPs), phospholipase A2 (PLA2), and L-amino acid oxidase (LAAO), as well as erythrolysis, coagulopathy, and local tissue damage assays. Results demonstrated dose-dependent neutralization of venom-induced proteolytic, PLA2, and LAAO activities, with over 80% inhibition of SVMPs and SVSPs, near-complete neutralization of PLA2, and partial inhibition of LAAO. Hemolytic, edemagenic, hemorrhagic, and myotoxic effects of V. ammodytes venom were efficiently mitigated.
This antivenom specifically recognizes immunogenic proteins of V. ammodytes and cross-reacts with other medically relevant Viperidae venoms, as confirmed by SDS-PAGE, Western bloting, and competitive ELISA. Potency testing demonstrated that antivenom exceeds European Pharmacopoeia standards for V. ammodytesV. aspis, and V. berus, as well as providing partial protection against Macrovipera lebetina and Montivipera xanthina, supporting its broad therapeutic relevance and highlighting the importance of functional cross-reactivity assays in antivenom evaluation.
Zivkovic, I., Vasic, M., Petrusic, M., Blagojevic, V., Dragacevic, L., & Lukic, I. (2026). A comprehensive preclinical assessment of Viekvin antivenom: Evaluation of neutralization efficacy and cross-reactivity toward European snake venoms. Toxicon, 109040. https://doi.org/10.1016/j.toxicon.2026.109040